相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
B cells from patients with multiple sclerosis. induce cell death via apoptosis in neurons in vitro
Robert P. Lisak et al.
JOURNAL OF NEUROIMMUNOLOGY (2017)
Cladribine - an old newcomer for pulsed immune reconstitution in MS
Heinz Wiendl
NATURE REVIEWS NEUROLOGY (2017)
Alemtuzumab CARE-MS I 5-year follow-up Durable efficacy in the absence of continuous MS therapy
Eva Havrdova et al.
NEUROLOGY (2017)
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
S. L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab
David Baker et al.
JAMA NEUROLOGY (2017)
Depletion of CD20 B cells fails to inhibit relapsing mouse experimental autoimmune encephalomyelitis
Eseberuo Sefia et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2017)
Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis
Cesar Alvarez-Gonzalez et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2017)
Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis
David Baker et al.
EBIOMEDICINE (2017)
Clonal relationships of CSF B cells in treatment-naive multiple sclerosis patients
Erica L. Eggers et al.
JCI INSIGHT (2017)
Both cladribine and alemtuzumab may effect MS via B-cell depletion
David Baker et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2017)
An observational study of alemtuzumab following fingolimod for multiple sclerosis
Mark Willis et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2017)
B-cell populations discriminate between pediatric- and adult-onset multiple sclerosis
Alexander Schwarz et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2017)
Therapeutic target of memory B cells depletion helps to tailor administration frequency of rituximab in myasthenia gravis
Christine Lebrun et al.
JOURNAL OF NEUROIMMUNOLOGY (2016)
Immunologic profiles of multiple sclerosis treatments reveal shared early B cell alterations
James Dooley et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2016)
Multiple Sclerosis and T Lymphocytes: An Entangled Story
Laurine Legroux et al.
JOURNAL OF NEUROIMMUNE PHARMACOLOGY (2015)
Tissue-based map of the human proteome
Mathias Uhlen et al.
SCIENCE (2015)
No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine
Julia Pakpoor et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2015)
Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients
Arumugam Palanichamy et al.
JOURNAL OF IMMUNOLOGY (2014)
Comparison of the in vitro and in vivo metabolism of Cladribine (Leustatin, Movectro) in animals and human
Holger Scheible et al.
XENOBIOTICA (2013)
A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum Disorder
Su-Hyun Kim et al.
JAMA NEUROLOGY (2013)
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
Jeffrey A. Cohen et al.
LANCET (2012)
Cladribine: Mode of Action and Implications for Treatment of Multiple Sclerosis
Thomas P. Leist et al.
CLINICAL NEUROPHARMACOLOGY (2011)
Cladribine inhibits cytokine secretion by T cells independently of deoxycytidine kinase activity
Bruno Laugel et al.
JOURNAL OF NEUROIMMUNOLOGY (2011)
Reference values for B cell subpopulations from infancy to adulthood
H. Morbach et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
Gavin Giovannoni et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells
Maria Mamani-Matsuda et al.
BLOOD (2008)
LMP1 signaling can replace CD40 signaling in B cells in vivo and has unique features of inducing class-switch recombination to IgG1
Julia Rastelli et al.
BLOOD (2008)
Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy
Jennifer H. Anolik et al.
ARTHRITIS AND RHEUMATISM (2007)
The 5′-nucleotidases as regulators of nucleotide and drug metabolism
SA Hunsucker et al.
PHARMACOLOGY & THERAPEUTICS (2005)
A gene atlas of the mouse and human protein-encoding transcriptomes
AI Su et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
分享论文
